

Edgar Filing: MEDIMMUNE INC /DE - Form 8-K

MEDIMMUNE INC /DE
Form 8-K
June 30, 2003

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report
June 27, 2003

MedImmune, Inc.
(Exact name of registrant as specified in its charter)

Delaware	0-19131	52-1555759
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(I. R. S. Employer Identification No.)

35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (301) 417-0770

ITEM 9. Regulation FD Disclosure

On June 27, 2003, MedImmune, Inc. (the "Company"), issued a press release announcing that it is holding a Business Review Meeting to provide analysts and investors an overview of its opportunities for long-term growth. The Company also announced that it is reconfirming its full-year guidance and increasing its guidance for the second quarter. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 7. Exhibits

c. Exhibits

Exhibit -----	Description -----
Ex. 99.1	Press release, dated June 27, 2003, "MedImmune's Business Review Meeting to Provide Overview of Opportunities for Long-Term Growth"

Edgar Filing: MEDIMMUNE INC /DE - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly to be signed on its behalf by the undersigned thereunto duly authorized.

MEDIMMUNE, INC.

Date: June 27, 2003

/s/: Lota S. Zoth
Lota S. Zoth
Vice President and Controller